000			03319nam a2200421 i 4500
999			_c112605 _d112605
001			112605
003			ES-MaUEC
005			20230213163511.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			190211s2019 gw a o |||| 0|eng d
020			_a9783030029760
024	7		_a10.1007/978-3-030-02976-0 _2doi
040			_bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC392 _b2019 EB
245	0	0	_aPlacebos and Nocebos in Headaches _cedited by Dimos D. Mitsikostas, Fabrizio Benedetti
264		1	_aCham _bSpringer International Publishing _c2019
300			_a1 recurso en línea (IX, 142 páginas) _b5 ilustraciones, 3 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aHeadache _x2197-652X
490	0		_aMedicine (Springer-11650)
505	0		_a1 Headache Classification and Diagnosis -- 2 The burden of headache -- 3 Patient centred approach in headaches -- 4 Unmet needs in headache management -- 5 Mechanisms of pain and headache -- 6 The reward system -- 7 Mechanisms of placebo -- 8 Mechanisms of nocebo -- 9 Placebo in headache treatment -- 10 Nocebo in headache treatment. .
520	3		_aThis book discusses the role of placebos and nocebos in the treatment of headache disorders. These disorders are usually treatable, but safety and tolerability issues mean that available preventive treatments have often limited success, even in the right hands - one in five patients treated with a migraine preventive pharmaceutical agent discontinues treatment for those reasons. The nocebo effect plays a role here, with patients' negative expectation and previous unpleasant treatment experiences creating negative belief in the treatment's benefits and safety, which in turn limits treatment outcomes and adherence significantly. In RCTs on migraine prevention, one in 20 patients treated with a placebo discontinued treatment because of adverse events, indicating a considerable nocebo effect; the fewer potential adverse events described in the consent form, the smaller the nocebo effect. As such, physicians treating headache sufferers should acknowledge nocebo as a significant cofactor for treatment adherence and failure, and plan techniques to limit the effects, such as patient education and close follow-up. This highly informative and painstakingly presented book provides scientific insights for professionals and scholars with an interest in internal medicine, neurology and pain medicine. .
988			_aSpringer_Medicine_2019
650		7	_2embne _aCefalalgia _9139470
650		7	_2embne _aDolor _9170361 _xTratamiento
700	1		_aMitsikostas, Dimos D. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _997019
700	1		_aBenedetti, Fabrizio _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _986887
710	2		_aSpringerLink (Online service) _9106996
776	0	8	_iPrinted edition: _z9783030029753
776	0	8	_iPrinted edition: _z9783030029777
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-02976-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_dz _b02/2023 _eb _zSI